357 related articles for article (PubMed ID: 33525637)
1. Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance.
Cetin R; Quandt E; Kaulich M
Cells; 2021 Jan; 10(2):. PubMed ID: 33525637
[TBL] [Abstract][Full Text] [Related]
2. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
3. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
[TBL] [Abstract][Full Text] [Related]
4. Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML.
Basheer FT; Vassiliou GS
Curr Opin Genet Dev; 2019 Feb; 54():83-87. PubMed ID: 31063922
[TBL] [Abstract][Full Text] [Related]
5. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
[TBL] [Abstract][Full Text] [Related]
6. Using functional genomics to overcome therapeutic resistance in hematological malignancies.
Alvarez-Calderon F; Gregory MA; DeGregori J
Immunol Res; 2013 Mar; 55(1-3):100-15. PubMed ID: 22941562
[TBL] [Abstract][Full Text] [Related]
7. Functional Genomics for Cancer Drug Target Discovery.
Haley B; Roudnicky F
Cancer Cell; 2020 Jul; 38(1):31-43. PubMed ID: 32442401
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
MacLeod G; Bozek DA; Rajakulendran N; Monteiro V; Ahmadi M; Steinhart Z; Kushida MM; Yu H; Coutinho FJ; Cavalli FMG; Restall I; Hao X; Hart T; Luchman HA; Weiss S; Dirks PB; Angers S
Cell Rep; 2019 Apr; 27(3):971-986.e9. PubMed ID: 30995489
[TBL] [Abstract][Full Text] [Related]
9. Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance.
Alyateem G; Wade HM; Bickert AA; Lipsey CC; Mondal P; Smith MD; Labib RM; Mock BA; Robey RW; Gottesman MM
Cancer Gene Ther; 2023 Aug; 30(8):1043-1050. PubMed ID: 37029320
[TBL] [Abstract][Full Text] [Related]
10. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?
Taylor J; Woodcock S
J Biomol Screen; 2015 Sep; 20(8):1040-51. PubMed ID: 26048892
[TBL] [Abstract][Full Text] [Related]
11. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
12. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
[TBL] [Abstract][Full Text] [Related]
13. Pooled CRISPR-Based Genetic Screens in Mammalian Cells.
Chan K; Tong AHY; Brown KR; Mero P; Moffat J
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31545321
[TBL] [Abstract][Full Text] [Related]
14. New strategies for targeting drug combinations to overcome mutation-driven drug resistance.
Wang L; Wang H; Song D; Xu M; Liebmen M
Semin Cancer Biol; 2017 Feb; 42():44-51. PubMed ID: 27840276
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
Tan DS; Gerlinger M; Teh BT; Swanton C
Eur J Cancer; 2010 Aug; 46(12):2166-77. PubMed ID: 20413300
[TBL] [Abstract][Full Text] [Related]
16. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.
Luo J
Trends Cancer; 2016 Jun; 2(6):313-324. PubMed ID: 28603775
[TBL] [Abstract][Full Text] [Related]
18. Functional-genetic approaches to understanding drug response and resistance.
Hinterndorfer M; Zuber J
Curr Opin Genet Dev; 2019 Feb; 54():41-47. PubMed ID: 30951975
[TBL] [Abstract][Full Text] [Related]
19. Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening.
Sun N; Petiwala S; Wang R; Lu C; Hu M; Ghosh S; Hao Y; Miller CP; Chung N
BMC Genomics; 2019 Mar; 20(1):225. PubMed ID: 30890156
[TBL] [Abstract][Full Text] [Related]
20. Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant P. aeruginosa.
Xu Z; Li M; Li Y; Cao H; Miao L; Xu Z; Higuchi Y; Yamasaki S; Nishino K; Woo PCY; Xiang H; Yan A
Cell Rep; 2019 Nov; 29(6):1707-1717.e3. PubMed ID: 31693906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
